

## **PRESS RELEASE**

FOR IMMEDIATE RELEASE

25<sup>th</sup> of July 2019

Contact: [contractes.aguas@gencat.cat](mailto:contractes.aguas@gencat.cat)

Agència de Qualitat i Avaluació Sanitària de Catalunya (AQuAS)

C. Roc Boronat, 81-95

08005 Barcelona

SPAIN

### ***Request for Tender “ANTI-SUPERBUGS PCP”***

The Horizon 2020-funded project named ANTI-SUPERBUGS PCP (Grant Agreement : 688878) will publish the call for tender on the **26<sup>th</sup> of July 2019**. The Deadline for submission of proposals will be on the **28<sup>th</sup> of October 2019**.

Six leading European procuring entities, under the lead of AQuAS, challenge the industry to develop **smart ICT solutions able to detect the presence of resistant microorganisms, give real-time feedback to the user and at the same time share the information with the healthcare provider electronic record systems, linking the infection with the place of the detection.**

The Available budget for the research, development and testing of these innovative solutions is **3.45 million Euro** (VAT included).

The call documents will be published on the TED platform (*The link will be available on the project website : <http://antisuperbugs.eu> and the public procurement platform [https://contractaciopublica.gencat.cat/ecofin\\_pscp/AppJava/en\\_GB/notice.pscp?reqCode=viewCn&idDoc=50080299](https://contractaciopublica.gencat.cat/ecofin_pscp/AppJava/en_GB/notice.pscp?reqCode=viewCn&idDoc=50080299).*

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.

Each selected operator will be awarded a framework agreement that covers 3 R&D phases:

- Phase 1: Up to solution design
- Phase 2: Up to a validated prototype
- Phase 3: Up to original development, validation and testing of a limited set of first products or services.



The procurement – from the tender procedure until the subsequent performance of contracts – is expected to start in 28/07/2019 and to end in 29/08/2021.

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions beyond the Buyer Group.

This is a joint procurement involving different countries, and the state applicable national procurement law is the Spanish one.

The lead procurer ([Agència de Qualitat i Avaluació Sanitària de Catalunya](#)) is appointed to coordinate and lead the joint PCP, and to sign and award the framework agreement and the specific contracts for all phases of the PCP, in the name and on behalf of the following Buyers Group:

- [ICO/ VINCat](#) (Catalan Institute of Oncology/Catalan Nosocomial Infections Surveillance Programme), Spain
- [UKA](#) (Aachen University Hospital), Germany
- [STH](#) (Sheffield Teaching Hospitals NHS Foundation Trust), UK
- [PAT](#) (Provincia Autonoma di Trento), Italy
- [HELIOS](#) (HELIOS Universitätsklinikum Wuppertal), Germany
- [FMT](#) (Fundació Mutua de Terrassa), Spain.

The Lead Procurer is not part of the Buyers Group and the EU is not participating as a contracting authority in this procurement.

The consortium comprises also the following partners, who provide a scientific-technical and/or legal support :

- [RISE](#) RESEARCH INSTITUTES OF SWEDEN AB - RISE
- [Sara Bedin](#), Independent expert on Innovation Public Procurement and PCP specialist

